Pasithea therapeutics to present at the h.c. wainwright 26th annual global investment conference

South san francisco, calif. and miami, aug. 28, 2024 (globe newswire) -- pasithea therapeutics corp. (nasdaq: ktta) (“pasithea” or the “company”) a clinical-stage biotechnology company developing pas-004, a next-generation macrocyclic mek inhibitor, for the treatment of neurofibromatosis type 1 (nf1) and other cancer indications, today announced that members of its management team will deliver a company presentation at the h.c.
KTTA Ratings Summary
KTTA Quant Ranking